OrthoPediatrics (NASDAQ:KIDS) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of OrthoPediatrics (NASDAQ:KIDS) in a research note issued to investors on Tuesday, Benzinga reports. JMP Securities currently has a $50.00 target price on the stock.

A number of other equities research analysts have also weighed in on KIDS. Truist Financial lowered shares of OrthoPediatrics from a buy rating to a hold rating and reduced their price objective for the company from $39.00 to $31.00 in a report on Thursday, January 25th. Needham & Company LLC reaffirmed a buy rating and set a $37.00 price target on shares of OrthoPediatrics in a report on Wednesday, April 10th.

OrthoPediatrics Price Performance

KIDS stock opened at $34.70 on Tuesday. The business’s 50-day moving average is $28.80 and its two-hundred day moving average is $29.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.44 and a quick ratio of 2.90. The firm has a market capitalization of $825.51 million, a P/E ratio of -37.72 and a beta of 1.16. OrthoPediatrics has a 1 year low of $23.10 and a 1 year high of $48.47.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The firm had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. Analysts anticipate that OrthoPediatrics will post -1.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the transaction, the general counsel now owns 52,403 shares in the company, valued at $1,445,798.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 2,741 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the sale, the general counsel now owns 52,403 shares in the company, valued at $1,445,798.77. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David R. Bailey sold 3,213 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,646.67. Following the completion of the sale, the chief executive officer now directly owns 139,384 shares of the company’s stock, valued at $3,845,604.56. The disclosure for this sale can be found here. Insiders have sold 17,253 shares of company stock worth $477,375 in the last ninety days. 31.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC grew its holdings in shares of OrthoPediatrics by 16,283.3% during the fourth quarter. CWM LLC now owns 983 shares of the company’s stock worth $32,000 after buying an additional 977 shares during the last quarter. RiverPark Advisors LLC purchased a new position in shares of OrthoPediatrics in the 3rd quarter valued at approximately $35,000. International Assets Investment Management LLC increased its holdings in shares of OrthoPediatrics by 3,151.4% in the fourth quarter. International Assets Investment Management LLC now owns 1,203 shares of the company’s stock valued at $37,000 after purchasing an additional 1,166 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of OrthoPediatrics by 136.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,341 shares of the company’s stock worth $107,000 after purchasing an additional 1,927 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of OrthoPediatrics by 180.8% during the first quarter. Quantbot Technologies LP now owns 7,091 shares of the company’s stock worth $207,000 after purchasing an additional 4,566 shares during the period. 69.05% of the stock is owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.